Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12782840 | 0.92 | SCN3A (0.62) | SCN3AALDH1A1MEN1KMT2APKM | |
| SCHEMBL12782783 | 0.91 | SCN3A (0.62) | SCN3AALDH1A1SCN9AMEN1KMT2A | |
| SCHEMBL12783349 | 0.89 | SCN3A (0.60) | SCN3AALDH1A1PKMSCN1BSCN8A | |
| SCHEMBL12782944 | 0.89 | SCN3A (0.62) | SCN3AALDH1A1SCN9APKMSCN1B | |
| SCHEMBL12783343 | 0.87 | SCN3A (0.55) | SCN3ASCN9APKMSCN1BSCN8A | |
| SCHEMBL12782931 | 0.85 | SCN3A (0.84) | SCN3ALMNASMN1; SMN2ALDH1A1SCN9A | |
| SCHEMBL12845590 | 0.84 | SCN3A (0.71) | SCN3ASMN1; SMN2ALDH1A1SCN9AMEN1 | |
| SCHEMBL12845725 | 0.84 | SCN3A (0.59) | SCN3ASMN1; SMN2ALDH1A1SCN9AMEN1 | |
| SCHEMBL2075384 | 0.84 | SCN3A (0.57) | SCN3ALMNASMN1; SMN2SCN9A | |
| SCHEMBL12845613 | 0.84 | SCN3A (0.53) | SCN3ALMNASMN1; SMN2SCN9ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | CACNA1C, CACNA1B, CACNA1D | SCN3A 17/4885LMNA 2631/4885SMN1; SMN2 2130/4885 |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | CACNA1C, CACNA1B, CACNA1D | SCN3A 17/4885LMNA 2631/4885SMN1; SMN2 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.